PTC Therapeutics Inc

+0.68 (+1.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.81B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$184.78 Million
Adjusted EPS-$1.41
See more estimates
10-Day MA$50.69
50-Day MA$40.38
200-Day MA$38.67
See more pivots

PTC Therapeutics Inc Stock, NASDAQ:PTCT

100 Corporate Court, South Plainfield, New Jersey 07080-2449
United States of America
Phone: +1.908.222.7000
Number of Employees: 1177


PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.